FibroGen, Inc

FibroGen discovers and develops therapeutics for serious unmet medical needs. Lead product candidates include Pamrevlumab for locally advanced pancreatic cancer and Roxadustat for anemia in chronic kidney disease and myelodysplastic syndromes. Roxadustat has completed Phase III clinical development for CKD. The company has agreements with Astellas Pharma Inc. and AstraZeneca AB.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

11.3 USD

Potential

-100%

Strengths

The company has high returns. ROIC (90.49%) is higher than the sector mean (6.02%).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	90.5%
Net Debt/EBITDA	100.0